Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Bent Jakobsen is a pioneer of T-cell receptor therapy for cancer with over two decades of experience establishing and providing scientific direction to leading T-cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and before this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. He is currently the Chief Executive Officer of Accession Therapeutic Ltd. and holds non-executive director positions in several Biotechnology companies.
